OBI-992, an investigational TROP2-targeted ADC, is composed of a novel TROP2 antibody (R4702) conjugated to the topoisomerase I (TOP1) inhibitor exatecan through a hydrophilic enzyme-cleavable linker...ADCs sacituzumab govitecan (SG) and datopotamab deruxtecan (Dato-DXd) were used as benchmarks for OBI-992...Moreover, substantial enhancement of cytotoxicity and DNA damage was found in the combination of OBI-992 with a poly (ADP-ribose) polymerase (PARP) inhibitor (talazoparib). Taken together, the findings in this study support further clinical development of OBI-992.

4 months ago

Preclinical • Journal • PARP Biomarker

TACSTD2 (Tumor Associated Calcium Signal Transducer 2)

Talzenna (talazoparib) • Trodelvy (sacituzumab govitecan-hziy) • Datroway (datopotamab deruxtecan) • OBI-992

6ms

OBI-992, a Novel TROP2-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models. (PubMed, Mol Cancer Ther)

This study evaluated and compared the antitumor activity of OBI-992 with that of benchmark TROP2-targeted ADCs datopotamab deruxtecan (Dato-DXd) and sacituzumab govitecan (SG) in cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models...The combination of OBI-992 at suboptimal doses with either poly (ADP-ribose) polymerase (PARP) inhibitors or an immune check point inhibitor produced synergistic antitumor effects in mouse models. Taken together, these translational results support further development of OBI-992 as a cancer therapy.

6 months ago

Preclinical • Journal • PARP Biomarker

TACSTD2 (Tumor Associated Calcium Signal Transducer 2)

TROP2 positive

Trodelvy (sacituzumab govitecan-hziy) • Datroway (datopotamab deruxtecan) • OBI-992

1year

A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)

P1/2, N=117, Recruiting, OBI Pharma, Inc

1 year ago

New P1/2 trial • Metastases

OBI-992